If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5 Phase III data demonstrated clinically meaningful 35.1% proteinuria reduction6; also, a stabilization of estimated glomerular filtration rate (eGFR) – a key measure of kidney function – was observed6-8 ​C3G is typically diagnosed in young adults2-5; approximately half of patients progress to kidney failure within 10 ...

Group 1 - The article suggests increasing the position in Novartis due to positive momentum, with the stock price rising nearly 10% since mid-December 2024 [1] - The analysis indicates that buy-side hedge professionals are conducting fundamental, income-oriented, long-term analysis across various sectors in developed markets [1] Group 2 - The author has a beneficial long position in Novartis shares, indicating a personal investment interest [2]

The pharmaceutical company's pipeline remains robust, which could translate into decent core EPS growth prospects.Since last October, Novartis' shares have lagged the S&P 500 index.This article was coproduced with Kody Kester.Introducing iREIT®Join iREIT® on Alpha today to get the most in-depth research that includes REITs, mREIT, Preferreds, BDCs, MLPs, ETFs, Builders, and Asset Managers. Our iREIT® Tracker provides data on over 250 tickers with our quality scores, buy targets, and trim targets.We recently ...

Last week, Swiss pharma giant Novartis (NVS) reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges) of $1.98 per share easily beat the Zacks Consensus Estimate of $1.81 and were up from $1.53 reported a year ago.Revenues of $13.15 billion rose 15% from the year-ago reported figure and beat the Zacks Consensus Estimate of $12.97 billion. On a constant currency basis, sales increased 16%, driven by the momentum i ...

Swiss pharma giant Novartis AG (NVS) reported better-than-expected results for the fourth quarter of 2024. Core earnings (excluding one-time charges) of $1.98 per share easily beat the Zacks Consensus Estimate of $1.81 and were up from $1.53 reported a year ago. The year-over-year growth was driven by strong growth in sales.Revenues of $13.15 billion climbed 15% from the year-ago reported figure. On a constant currency basis, sales increased 16%, driven by the momentum in Entresto, Kesimpta, Kisqali, Cosent ...

Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Q4 2024 Results Q4 2024 Results Investor presentation January 31, 2025 Investor presentation January 31, 2025 Novartis Q4 Results | January 31, 2025 1 Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities ...

Novartis (NVS) reported $13.15 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 15.1%. EPS of $1.98 for the same period compares to $1.53 a year ago.The reported revenue represents a surprise of +1.44% over the Zacks Consensus Estimate of $12.97 billion. With the consensus EPS estimate being $1.81, the EPS surprise was +9.39%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

Annual Report 2024 Annual Report 2024 Chair's letter In our first full-year as a pure-play medicines company, Novartis delivered strong results, with double-digit growth in sales and net profit in 2024. The performance validates our strategy and gives us confidence that we are well prepared to grow by focusing on our key thera- peutic areas and technology platforms. The strategic shift from a diversified life sciences com- pany to a focused medicines organization over the last decade has proven to be the ri ...

Pricing and Reimbursement Pressures - Novartis faces significant pricing and reimbursement pressures, impacting product pricing and availability due to government-imposed price reductions and public controversies[34]. - The company has committed to a "maximum fair price" for its cardiovascular drug Entresto under the US Inflation Reduction Act for 2026 to avoid penalties[34]. - Pricing pressures in developed markets, such as the US IRA targeting drug prices, may negatively impact revenue and net sales[100]. - Price controls and drug reimbursement programs are expected to negatively impact the prices of pharmaceutical products due to political pressures[207]. - The Inflation Reduction Act of 2022 mandates price negotiations for certain Medicare drugs, affecting pricing strategies for eligible products[208]. - Novartis anticipates ongoing global pricing pressures, which may hinder the ability to achieve adequate returns on product investments[215]. Product Development and Innovation - Novartis emphasizes the importance of successfully launching new products to replace revenue lost to generic and biosimilar competition, which is critical for maintaining business growth[35]. - The company is investing in advanced technologies, including artificial intelligence (AI), to enhance research and development efficiency and maintain competitive advantage[39]. - The company is committed to leveraging its technology platforms to discover and develop innovative medicines in core therapeutic areas, which is vital for future growth[38]. - The company has multiple projects in the Confirmatory Development stage, including AVXS-101 for spinal muscular atrophy and Beovu for diabetic retinopathy, with planned filings in 2025 and 2024 respectively[153]. - The company aims to facilitate rapid approvals in developing countries through the MAGHP procedure, enhancing global access to its therapies[153]. Intellectual Property and Competition - Novartis relies on intellectual property rights to protect its products, but these rights can be challenged, affecting market exclusivity and revenue potential[44]. - The company faces significant risks related to the loss of intellectual property protection, which can lead to a substantial reduction in net sales and operating income[47]. - The introduction of generic or biosimilar competition can significantly impact the company's income, depending on various factors such as the timing of competitor launches and regulatory approvals[50]. - The company is exposed to potential claims of intellectual property infringement, which can be costly and may delay product launches[47]. - Third parties can challenge Novartis's intellectual property rights through various legal proceedings, making outcomes difficult to predict[222]. Regulatory and Compliance Challenges - The regulatory landscape is becoming increasingly complex, with heightened scrutiny on long-term data and post-approval requirements, raising costs and risks associated with maintaining product approvals[42]. - The healthcare industry is subject to evolving legal and regulatory requirements, which may incur substantial compliance costs and affect business practices[72]. - The FDA requires compliance with rigorous standards throughout the product lifecycle, including post-approval studies for long-term effects[199]. - In the EU, the centralized procedure for drug authorization is mandatory for biotechnology products and must be completed within 210 days[203]. - Noncompliance with data privacy laws could result in significant penalties and disrupt operations, given the reliance on personal data for business[90]. Talent Management and Workforce Challenges - The company must effectively manage its talent and external workforce to achieve its business objectives and mitigate risks[65]. - The company faces challenges in attracting and retaining top talent in critical areas such as biology, immunology, and digital IT, amid increasing competition from other pharmaceutical and biotechnology firms[66]. - Geographic mobility of talent is decreasing in key markets like the US and China, limiting the external talent supply necessary for growth[67]. - Novartis employs 75,883 full-time equivalent employees as of December 31, 2024, and its products are sold in approximately 120 countries[128]. - Novartis has 19,135 full-time equivalent field force employees as of December 31, 2024, to support marketing and sales efforts[164]. Financial Performance and Risks - In 2024, Novartis achieved net sales from continuing operations of USD 50.3 billion, with net income from continuing operations amounting to USD 11.9 billion[128]. - As of December 31, 2024, the company had USD 21.4 billion in non-current financial debt and USD 8.2 billion in current financial debt, which may limit cash flow for capital expenditures and increase vulnerability to economic downturns[113]. - The company may incur significant tax liabilities if the spin-off of Sandoz does not qualify as a tax-neutral transaction[59]. - Changes in tax laws, including the OECD minimum tax regime, could increase the company's effective tax rate and lead to international tax disputes[108][109]. - Currency exchange rate fluctuations may significantly impact reported sales, costs, and earnings, as a substantial portion of earnings and expenditures are in currencies other than the US dollar[117][119]. Supply Chain and Operational Risks - The company may face supply chain disruptions due to reliance on specialized raw materials and single-source suppliers, impacting product availability[87]. - The presence of falsified medicines in distribution channels poses risks to patient safety and could lead to reputational and financial harm for the company[92]. - Manufacturing processes are complex and heavily regulated, with failures potentially leading to product recalls and significant reputational harm[83]. - The company actively manages ESG matters, which are increasingly scrutinized by stakeholders and can impact long-term sustainability[54]. - Cybersecurity threats pose a significant risk to the company's IT systems, potentially affecting critical business processes and leading to data breaches[60]. Acquisitions and Strategic Moves - The company completed the spin-off of Sandoz, its generics and biosimilars division, into a new independent company in 2023[58]. - In 2024, the company closed acquisitions of MorphoSys AG, Mariana Oncology, and Kate Therapeutics, enhancing its portfolio[51]. - Novartis acquired Mariana Oncology, a preclinical biotechnology company focused on novel radioligand therapies, enhancing its portfolio in solid tumors[190]. - Novartis acquired an 89.7% interest in MorphoSys AG, which includes late-stage and early-stage assets for myelofibrosis and solid tumors[191]. - The company completed the acquisition of the remaining shares of MorphoSys AG, making it a wholly-owned subsidiary[192].

An office building designed by Frank O. Gehry at the Novartis AG headquarters campus in Basel, Switzerland.Bloomberg | Getty ImagesSwiss pharmaceutical giant Novartis on Friday reported better-than-expected sales in the fourth quarter, but falling short of its own guidance over the full-year stretch.Fourth-quarter net sales rose 16% on a constant currency basis to $13.2 billion, compared to the $12.795 billion estimated by analysts in an LSEG poll.Quarterly adjusted core operating income came in at $4.86 bi ...